- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02689115
NFKB1 and IKK Epsilon in Rheumatoid Arthritis (NUIRA)
NF-KB1/IKK Epsilon Genetic Expression in Patients With Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a systemic and auto-immune disorder whose primary characteristic is the chronic inflammation of joints. The objective of this study was to evaluate whether there was an association between the NF-KB1/IKK epsilon genetic expression and the clinical activity in RA.
60 RA patients were included in the study, 30 with clinical activity and 30 with clinical remission The NF-KB1/IKK epsilon genetic expression was performed by real time quantitative Polymerase chain reaction (qPCR) through the Pfaffl method of relative quantification with Taqman probes.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Patients with a confirmed diagnosis of RA were allocated in two groups based on the Disease Activity Score 28 (DAS28): a) with clinical activity and b) with clinical remission. Key exclusion criteria were patients with any other inflammatory or autoimmune disease and patients with infections. The control group was represented by healthy patients Sample size
The sample size calculation was carried out through the following formula:
n= Nz2 pq /d2(N-1) +z2 pq With N=30, Z=2.46 (99% of confidence), p=0.9, q=0.1, d=0.05 (95% of accuracy). The sample size contained 20 patients with RA.
Anthropometric measurements Weight (kg) and height (m) were calculated in a mechanical column scale (SECA). The patients were classified according to their Body mass index (BMI, weight (Kg)/ height (m)2) as a) normal weight (BMI< 24.9), b) overweight (24.9 kg/m2 <BMI<29.9 kg/m2) and c) obese (BMI> 30 kg/m2).
Lymphocyte extraction Lymphocytes from peripheral blood were extracted using the ACK Lysing Buffer® (Life technologies, Grand Island, NY) kit. Briefly, a venous blood sample in EDTA tube (BD Vacutainer®, Franklin Lakes, NJ), was centrifuged at 3500 rpm during 5-8 minutes. The resulting intermediate white colored phase was extracted and placed in an eppendorf tube; 1 mL of ACK Lysing Buffer® was added and carefully re-suspended. Once again, the suspension was centrifuged at 3500 rpm during 5-8 minutes and the supernatant was discarded. This last step was repeated until the leukocyte package was completely white. Finally, it was added 100 mcl of ACK Lysing Buffer® and frozen at -70ºC for later use.
Genetic expression From the leukocyte package (approximately 10 to 15 mg), it was performed a messenger RNA (mRNA) extraction using the Magna Pure LC RNA isolation kit III (Roche) in the Magna Pure LC 2.0 Instrument. The A260/A280 nm absorbance ratio was >1.8 (quality) and total RNA concentration was calculated by determining absorbance at 260 nm established with the NanoPhotometer (Implen GmbH, Germany) and the extracts were adjusted to a concentration of 20 µg of DNA for the PCR reaction.
Subsequently, the cDNA was synthesized with the Transcriptor High Fidelity cDNA Synthesis Kit (Roche Applied Science). It was performed a real time polymerase chain reaction (qPCR), using the specific primers and probes for NF-KB1, IKK epsilon and 18s (as constitutive gene), using a 7500 Fast Real Time PCR System (Applied Biosystems, Applera UK, Cheshire, UK), mixing TaqMan® Universal PCR Master Mix and the specific probes for each gene NF-KB1 (Hs00765730-m1), IKK epsilon (Hs01063858-m1) and 18S (Hs99999901-s1), (Applied Biosystems, Applera UK, Cheshire, UK).
According to the Ct obtained from the two different groups it was calculated the relative units of expression through the Pfaffl relative quantification method, in which it was used as control a healthy patient.
Statistical analysis The statistical analysis was performed through the Sigmaplot software version 12.0. Parametric and non-parametric test were used in function to the variable distribution: among the parametric test that were performed to compare the groups, the Student´s T-test was included; the non-parametric tests applied were: The Mann-Whitney U test and the Shapiro-Wilk test. Finally, a receiver operating characteristic (ROC) was used for the analysis of the genetic expression of NF-KB1/IKK epsilon with the SPSS software version 22.0.
Study Type
Enrollment (Actual)
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Diagnosis criteria established by the American College of Rheumatology (ACR).
Exclusion Criteria:
- Patients with any other inflammatory, autoimmune or neoplastic disease and patients with infections.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Clinical activity
Patients with rheumatoid arthritis who met the criteria established by the American College of RheumatologyDisease Activity Score 28 (DAS28) > 3.6.
|
The genetic expression of NF-KB1 and IKK epsilon were quantified in both groups.
|
|
Clinical remission
Patients with rheumatoid arthritis with Disease Activity Score 28 (DAS28) < 2.4.
|
The genetic expression of NF-KB1 and IKK epsilon were quantified in both groups.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Relative genetic expression of NF-KB1 and IKK epsilon.
Time Frame: Within one month after the patient selection.
|
Within one month after the patient selection.
|
Collaborators and Investigators
Collaborators
Investigators
- Study Director: Hugo Mendieta Zerón, PhD., Asociación Científica Latina A.C.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2015/02
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rheumatoid Arthritis
-
Janssen Research & Development, LLCWithdrawnActive Rheumatoid Arthritis; Rheumatoid Arthritis
-
Centocor, Inc.CompletedRheumatoid Arthritis, Juvenile
-
Yuanyuan ZhangRecruitingRheumatoid Arthritis (RA) | Rheumatoid Arthritis-Associated Interstitial Lung Disease | Difficult-to-Treat Rheumatoid ArthritisChina
-
AmgenTerminated
-
Children's Hospital Medical Center, CincinnatiNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedJuvenile Rheumatoid ArthritisUnited States
-
AmgenImmunex CorporationCompletedJuvenile Rheumatoid Arthritis
-
Richard Burt, MDTerminated
-
Assistance Publique - Hôpitaux de ParisSociete Francaise de RhumatologieRecruiting
-
University Hospital, ToulouseCompletedRheumatoId ArthritisFrance
-
Amsterdam UMC, location VUmcEuropean CommissionCompletedRheumatoId ArthritisNetherlands, Germany, Portugal, Italy, Hungary, Romania, Slovakia
Clinical Trials on Genetic relative expression
-
University of FloridaNational Heart, Lung, and Blood Institute (NHLBI)CompletedHypertension | Gut InflammationUnited States
-
Azienda USL Reggio Emilia - IRCCSRecruiting
-
Chinese University of Hong KongRecruiting
-
Institut du Cancer de Montpellier - Val d'AurelleCompletedColorectal Cancer | Esophageal CancerFrance
-
Columbia UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); ROHHAD...RecruitingChildhood Obesity | Morbid ObesityUnited States
-
Duke UniversityCompletedHeart Failure, DiastolicUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruiting
-
Prisma Health-UpstateCompletedCOVID-19 | SARS-CoV-2 InfectionUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedBrain and Central Nervous System Tumors
-
Air Force Military Medical University, ChinaCompletedAcute Leukemia | Childhood Cancer | Cardiac ToxicityChina